Literature DB >> 8553673

Treatment of unresectable lung cancer with brachytherapy.

C Aygun1, J E Blum.   

Abstract

Endobronchial brachytherapy is an evolving treatment modality. Although standard clinical indications and dosage schedules have not yet been established, the wide range of individual experience overwhelmingly demonstrates its efficacy in palliating lung cancer patients who generally have limited treatment options. Although the exact complication rate is not known, it appears to be low and the potential benefits far outweigh the risks. The role of endobronchial brachytherapy for cure is less clear. For most instances "prolonged palliation" would be a more suitable term than "cure." Further data is needed to clarify the proper place of endobronchial brachytherapy as a boost to external beam radiation therapy. The dose, fractionation scheme, and timing relative to external beam radiation therapy are based on institutional preference at this time. The historical evolution, treatment technique, results, and complications of endobronchial brachytherapy are reviewed here.

Entities:  

Mesh:

Year:  1995        PMID: 8553673     DOI: 10.1007/bf00299778

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  22 in total

1.  REMOTE AFTERLOADING WITH INTRACAVITARY APPLICATORS.

Authors:  U K HENSCHKE; B S HILARIS; G D MAHAN
Journal:  Radiology       Date:  1964-08       Impact factor: 11.105

2.  Complications associated with brachytherapy alone or with laser in lung cancer.

Authors:  B Khanavkar; P Stern; W Alberti; J A Nakhosteen
Journal:  Chest       Date:  1991-05       Impact factor: 9.410

3.  Sequential comparison of low dose rate and hyperfractionated high dose rate endobronchial radiation for malignant airway occlusion.

Authors:  M Mehta; D Petereit; L Chosy; M Harmon; J Fowler; S Shahabi; B Thomadsen; T Kinsella
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

4.  Management of malignant airway compromise with laser and low dose rate brachytherapy. The Mayo Clinic experience.

Authors:  M F Schray; J C McDougall; A Martinez; D A Cortese; W M Brutinel
Journal:  Chest       Date:  1988-02       Impact factor: 9.410

5.  Consensus guidelines for high dose rate remote brachytherapy in cervical, endometrial, and endobronchial tumors. Clinical Research Committee, American Endocurietherapy Society.

Authors:  S Nag; A A Abitbol; L L Anderson; J C Blasko; A Flores; L B Harrison; B S Hilaris; A A Martinez; M P Mehta; D Nori
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-12-01       Impact factor: 7.038

6.  Hemorrhage from carcinoma of the lung.

Authors:  R R Miller; D H McGregor
Journal:  Cancer       Date:  1980-07-01       Impact factor: 6.860

7.  Impact of tumor control on survival in carcinoma of the lung treated with irradiation.

Authors:  C A Perez; M Bauer; S Edelstein; B W Gillespie; R Birch
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-04       Impact factor: 7.038

8.  High dose rate afterloading intraluminal brachytherapy in malignant airway obstruction of lung cancer.

Authors:  L F Chang; J Horvath; W Peyton; S S Ling
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-02-01       Impact factor: 7.038

9.  Treatment of non-small cell lung cancer with external beam radiotherapy and high dose rate brachytherapy.

Authors:  C Aygun; S Weiner; A Scariato; D Spearman; L Stark
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

10.  Cancer statistics, 1995.

Authors:  P A Wingo; T Tong; S Bolden
Journal:  CA Cancer J Clin       Date:  1995 Jan-Feb       Impact factor: 508.702

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.